Franklin Templeton’s Emerging Markets Equity team’s Michael Lai and Elizabeth Wu take a look at a new breed of innovative enterprises in China that could transform health care outcomes in the years ahead. READ MORE
Similar Posts:
- Heightened Regulatory Scrutiny in China: What Investors Need to Know (Franklin Templeton)
- Evergrande Crisis and Contagion Risks (Franklin Templeton)
- China’s Regulatory Tightening: Our View on Goals and Scope (Franklin Templeton)
- Chinese New Year: How Investors Might Navigate Markets in the Year of the Ox (Franklin Templeton)
- Evergrande and China: A Lehman Moment—or Less “Grande” Than That? (Franklin Templeton)
- The Race to Harness AI Technology in Asia (Franklin Templeton)
- China Health Care: A Rediscovered Sector Keeps Its Momentum (KraneShares)
- Templeton’s Chow: “No Reason the Goat and the Bull Cannot be Friends” (Mobius Blog)
- South Korea: A Shining Example of Emerging Market Leadership (Franklin Templeton)
- China: Innovation Superpower (Wellington Management)
- The New Emerging Markets Landscape: Policy Improvements Should Contribute to Increased Resilience (Franklin Templeton)
- Investor Sentiment Survey: What Emerging Market Investors Think (Franklin Templeton)
- Russia, Ukraine and China (Franklin Templeton)
- Changes to the Emerging Markets Club: China (A Shares), Argentina and Saudi Arabia (Franklin Templeton)
- Looking Past the Hang-Ups for Asia’s Smartphone Industry (Franklin Templeton)
